Eloxx Pharmaceuticals, Inc. (ELOX)

$0.17

-0.00 (-0.87%)
Rating:
Recommendation:
-
Symbol ELOX
Price $0.17
Beta 2.023
Volume Avg. 0.21M
Market Cap 14.732M
Shares () -
52 Week Range 0.14-1.66
1y Target Est -
DCF Unlevered ELOX DCF ->
DCF Levered ELOX LDCF ->
ROE -256.75% Strong Sell
ROA -134.22% Strong Sell
Operating Margin -
Debt / Equity 1717.94% Strong Buy
P/E -
P/B 8.13 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ELOX news


Mr. Robert Ward
Healthcare
Biotechnology
NASDAQ Global Market

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.